Michigan’s Armune Bioscience has been bought by Exact Science, which plans to expand its cancer diagnostics range with Armune’s prostate cancer test.
Armune Bioscience, a US-based prostate cancer diagnostics spinout from University of Michigan, has been acquired by oncological test manufacturer Exact Science for an undisclosed sum, Xconomy reported today.
The sale closed in mid-December 2017 but was not publicly revealed until earlier this month.
Founded in 2008, Armune has developed a diagnostic test for prostate cancer called Apifiny that scans a patient’s blood sample from for a distinct biomarker linked to the disease.
Apifiny is intended as a…
